← Product Code [NTH](/submissions/IM/subpart-e%E2%80%94immunology-laboratory-equipment-and-reagents/NTH) · K122554 # GENASIS SCANVIEW SYSTEM (K122554) _Applied Spectral Imaging , Ltd. · NTH · Feb 7, 2013 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/PA/subpart-e%E2%80%94immunology-laboratory-equipment-and-reagents/NTH/K122554 ## Device Facts - **Applicant:** Applied Spectral Imaging , Ltd. - **Product Code:** [NTH](/submissions/IM/subpart-e%E2%80%94immunology-laboratory-equipment-and-reagents/NTH.md) - **Decision Date:** Feb 7, 2013 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.4700 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The GenASIs ScanView System is an automated scanning microscope and image analysis system. It is intended for in vitro diagnostic use as an aiding tool to the pathologist or cytogeneticist in the detection, classification and enumeration of cells of interest based on color, intensity, size, pattern; and shape. The GenASIs ScanView System is indicated as an accessory to the following FDA cleared/approved devices to detect the following cell types: 1. CEP® X Spectrum Orange™/CEP® Y Spectrum Green™ DNA Probe Kit and is limited to the analysis of CEP XY probes via high magnification capture and analysis of interphase nuclei. CEP XY is indicated for use to assess the effectiveness of bone marrow transplantation in opposite-sex transplants. 2. Human breast cancer containing the HER-2/neu gene labeled in Red and the centromere of chromosome 17 labeled in Green via fluorescence in situ hybridization (FISH) in interphase nuclei from formalin-fixed, paraffin embedded human breast cancer tissue specimens with Vysis® PathVysion™ HER-2 DNA Probe kit. Results from the PathVysion™ Kit are intended for use as an adjunct to existing clinical and pathologic information used as prognostic factors in stage II, node-positive breast cancer patients. The PathVysion™ kit is further indicated as an aid to predict disease-free and overall survival in patients with stage II, node positive breast cancer, treated with adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) chemotherapy. 3. Cells in urine specimens, stained by fluorescence in situ hybridization (FISH) using Vysis UroVysion™ Bladder Cancer Kit to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus, from persons with hematuria suspected of having bladder cancer. The results are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer. 4. Gene rearrangements involving the ALK gene (2p23) via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens, using Vysis® ALK (Anaplastic Lymphoma Kinase) Break Apart FISH Probe kit. The GenASIs ALK System is indicated to aid in identifying those patients eligible for treatment with XALKORI® (crizotinib). The GenASIs ScanView System is to be used as an adjunctive automated enumeration tool in conjunction with manual visualization. ## Device Story GenASIs ScanView is an automated digital imaging system comprising a microscope, motorized stage, camera, and workstation. It processes FFPE NSCLC tissue slides hybridized with Vysis ALK Break Apart FISH probes. The system captures images of cells; identifies regions of interest; and enumerates orange, green, and fused (yellow) signals. Pathologists review a gallery of captured cells to approve, modify, or reject automated calls. The system calculates the percentage of positive cells for gene rearrangement to aid in identifying patients eligible for XALKORI (crizotinib) therapy. It functions as an adjunctive tool to manual visualization in clinical laboratory settings. ## Clinical Evidence Bench testing only. Method comparison study across four clinical sites using 179 FFPE NSCLC slides (including 9 equivocal cases) compared GenASIs ScanView to manual counting. Results showed 100% overall agreement (95% CI: 98%-100%), 100% negative percent agreement, and 100% positive percent agreement. Reproducibility and repeatability studies (within-day, between-day, between-system) showed 100% concordance for positive/negative diagnoses. ## Technological Characteristics Integrated digital imaging system: microscope, motorized X-Y stage, CCD camera, workstation. Software: GenASIs ScanView Version 7.0. Connectivity: Barcode reader for specimen ID. Sterilization: N/A. Energy: Electrical. Form factor: Benchtop workstation. ## Regulatory Identification An automated FISH enumeration system is a device that consists of an automated scanning microscope, image analysis system, and customized software applications for FISH assays. This device is intended for in vitro diagnostic use with FISH assays as an aid in the detection, counting and classification of cells based on recognition of cellular color, size, and shape, and in the detection and enumeration of FISH signals in interphase nuclei of formalin-fixed, paraffin-embedded human tissue specimens. ## Special Controls The device is classified as Class II under regulation 21 CFR 866.4700 with special controls. The special control guidance document " Class II Special Controls Guidance Document: Automated Fluorescence in situ Hybridization (FISH) Enumeration Systems" is available at www.fda.gov/cdrh/oivd/guidance/1550.pdf. *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Automated Fluorescence*in situ* Hybridization (FISH) Enumeration Systems.” See § 866.1(e) for the availability of this guidance document. ## Predicate Devices - ScanView System ([K110345](/device/K110345.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k122554 B. Purpose for Submission: Addition of the GenASI ALK System Application to the GenASI ScanView System for fluorescence *in situ* hybridization (FISH) of gene rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene (2p23) C. Manufacturer and Instrument Name: Applied Spectral Imaging Ltd. GenASIs ScanView System GenASI ALK System D. Type of Test or Tests Performed: Automated fluorescence *in situ* hybridization (FISH) detection and enumeration of rearrangements involving the ALK gene (2p23) in formalin-fixed paraffin embedded (FFPE) human non-small cell lung cancer (NSCLC) tissue specimens treated with the Vysis® ALK Break Apart FISH Probe Kit E. System Descriptions: 1. Device Description: The GenASIs ScanView is an integrated digital imaging system constructed of a microscope, motorized multi-slide stage, camera, and a workstation. It is designed to acquire images of cells and enables identification and examination of cells of interest. Pathologists can view and scan cells and record the image, using both bright field and fluorescent illumination. The acquired images can be enhanced, archived, retrieved and printed. The automated microscope enables Z motion of the slide and the motorized stage enables its X-Y motions. The microscope also includes motorized filter turret containing fluorescence filters. The Gen ASIs ALK System software application evaluates FISH in human NSCLC tissue specimens hybridized with the Vysis® ALK Break Apart FISH Probe Kit. {1} 2 2. Principles of Operation: The Gen ASIs ScanView System works with the Gen ASIs ALK System software application to evaluate FISH stained human NSCLC tissue specimens by the Vysis® ALK Break Apart FISH Probe Kit. The probe kit contains a mixture of two probes that are on opposite sides flanking the breakpoint of the ALK gene. The 3'-ALK probe hybridizes telomerically at the breakpoint and is labeled with Spectrum Orange and the 5'-ALK probe hybridizes centromerically at the breakpoint and is labeled with Spectrum Green. After hybridization with the ALK Probe, the 2p23 ALK region in its native state will be seen as two immediately adjacent or fused orange/green (yellow) signals (2F). However, if a t(2;5) or other chromosome rearrangement at the 2p23 ALK breakpoint region has occurred, one orange and one green signal will be seen, while the native ALK region will remain as an orange/green fusion signal. The user defines the regions containing tumor cells and manually captures cells from these regions. The system automatically defines the cells of interest and the pathologist then either chooses specific cells for analysis or the system analyzes all of the cells from the selected regions. At least 100 cells should be counted. The GenASIs ALK System application reports the counts of the orange, green and fused (yellow) signals in each cell and classifies it according to predefined cell categories. After the scanning, each cell is presented in a gallery and the pathologist can approve, modify or reject the call for each cell. The overall statistics are updated accordingly. Only after the pathologist confirms the final score is the calculated percent positive cells for the gene rearrangement printed out in a final report. 3. Modes of Operation: Semi-automated; manual capture of selected regions with computer-assisted interpretation 4. Specimen Identification: Barcode Reader 5. Specimen Sampling and Handling: Specimens are FFPENSCLC tissue specimens on glass slides hybridized with the Vysis® ALK Break Apart FISH Probe kit. Scanning more than one slide requires a specialized stage that supports a tray holding up to nine slides for automatic scanning {2} 6. Calibration: Calibration is performed by GenASI personnel at installation. Routine calibration by the user is not required. 7. Quality Control: The accuracy of the GenASIs ScanView System depends on the laboratory following the quality control instructions for the Vysis® ALK FISH Probe Kit. 8. Software: FDA has reviewed applicant’s Hazard Analysis and Software Development processes for this line of product types: Yes ☐ X or No ☐ F. Regulatory Information: 1. Regulation section: 21 CFR §866.4700 – Automated fluorescence *in situ* hybridization (FISH) enumeration systems 2. Classification: Class II 3. Product code: NTH – system, automated scanning microscope and image analysis for fluorescence *in situ* hybridization (FISH) assays 4. Panel: Immunology (82) G. Intended Use: 1. Indication(s) for Use: The GenASIs ScanView System is an automated scanning microscope and image analysis system. It is intended for *in vitro* diagnostic use as an aiding tool to the pathologist or cytogeneticist in the detection, classification and enumeration of cells of interest based on color, intensity, size, pattern; and shape. The GenASIs 3 {3} ScanView System is indicated as an accessory to the following FDA cleared/approved devices to detect the following cell types: 1. CEP® X Spectrum Orange™/CEP® Y Spectrum Green™ DNA Probe Kit and is limited to the analysis of CEP XY probes via high magnification capture and analysis of interphase nuclei. CEP XY is indicated for use to assess the effectiveness of bone marrow transplantation in opposite-sex transplants. 2. Human breast cancer containing the HER-2/neu gene labeled in Red and the centromere of chromosome 17 labeled in Green via fluorescence *in situ* hybridization (FISH) in interphase nuclei from formalin-fixed, paraffin embedded human breast cancer tissue specimens with Vysis® PathVysion™ HER-2 DNA Probe kit. Results from the PathVysion™ Kit are intended for use as an adjunct to existing clinical and pathologic information used as prognostic factors in stage II, node-positive breast cancer patients. The PathVysion™ kit is further indicated as an aid to predict disease-free and overall survival in patients with stage II, node positive breast cancer, treated with adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) chemotherapy. 3. Cells in urine specimens, stained by fluorescence *in situ* hybridization (FISH) using Vysis UroVysion™ Bladder Cancer Kit to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus, from persons with hematuria suspected of having bladder cancer. The results are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer. 4. Gene rearrangements involving the ALK gene (2p23) via fluorescence *in situ* hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens, using Vysis® ALK (Anaplastic Lymphoma Kinase) Break Apart FISH Probe kit. The GenASIs ALK System is indicated to aid in identifying those patients eligible for treatment with XALKORI® (crizotinib). The GenASIs ScanView System is to be used as an adjunctive automated enumeration tool in conjunction with manual visualization. 2. Special Conditions for Use Statement(s): For prescription use only. 4 {4} 5 # H. Substantial Equivalence Information: 1. Predicate Device Name(s) and 510(k) numbers: Applied Spectral Imaging, ScanView System, k110345 2. Comparison with Predicate Device: | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Methodology | Fluorescence in situ hybridization (FISH) | same | | Device components | Microscope, PC, keyboard, control panel, color monitor, CCD camera, motorized stage | same | | Differences | | | | --- | --- | --- | | Item | Device | Predicate | | Probe Kit | Vysis ALK Break Apart FISH Probe Kit | Vysis UroVysion™ Bladder Cancer Kit | | Specimen type | Lung Cancer Tissue | Urine | | Software version | GenASIx ScanView Version 7.0 | ScanView Version 6.0 | # I. Special Control/Guidance Document Referenced (if applicable): Class II Special Controls Guidance Document: Automated Fluorescence in situ Hybridization (FISH) Enumeration Systems, 23 May 2005. Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests”; March 2007. Guidance for the Content of Premarket Submission for Software Contained in Medical Device, CDRH, May 2005. # J. Performance Characteristics: 1. Analytical Performance: a. Accuracy: Slides containing formalin-fixed paraffin-embedded (FFPE) tissue specimens from patients with non-small cell lung cancer (NSCLC) were hybridized with {5} the FDA approved Vysis ALK Break Apart FISH Probe Kit according to the manufacturer's instructions. At each clinical site, archived slides from NSCLC tissue specimens, previously counted and analyzed manually in the last 6 months, were used for the test. Negative cases were selected sequentially from a known bank of negative samples. All positive and equivocal slides that were available during the period of the comparison studies were used for the analysis in order to have an adequate number of slides in each of the categories. Patients with NSCLC that were negative for the EGFR test were included in the study. At four clinical sites, a total of 179 slides including 9 cases in the equivocal zone (10-50%) were analyzed. The GenASIs ScanView operator had no prior knowledge of the manual counting results. Method comparison results for all four sites combined are presented below in Table 1: Table 1: Method Comparison of GenASIs ScanView vs. Manual Method - All sites combined | | Manual Method | | | | | --- | --- | --- | --- | --- | | | | Negative | Positive | Total | | GenASIs ScanView Method | Negative | 147 | 0 | 147 | | | Positive | 0 | 32 | 32 | | | Total | 147 | 32 | 179 | Overall agreement: $100\%$ (95% CI: 98%-100%) Negative percent agreement: $100\%$ (95% CI: 97.5%-100%) Positive percent agreement: $100\%$ (95% CI: 89.1%-100%) # b. Precision/Reproducibility: A panel of 10 slides chosen by the manual counting results, 4 of which were negative (<10%), 3 equivocal (10-50%) and 6 positive (>50%) were evaluated for repeatability and reproducibility of diagnosis (positive/negative) for the following: - Within-day/within system: each one of the slides was evaluated three times on the same system on the same day. - Between days: slides were assessed on three separate days on the same system (interval between assessments was at least five days). - Between systems: three GenASIs ScanView ALK Systems were used at three different sites by three different operators. Diagnoses over different days and systems were $100\%$ concordant for positive vs. negative results, as were within-day results. Both repeatability and reproducibility in the study were $100\%$ . {6} Mean percent positive cells, standard deviation and % coefficient of variation for each study are presented in Table 2 below. For the negative specimens %CV values are not applicable as a higher degree of variance is to be expected in negative or low positive specimens due to the fewer signals. Table 2: Repeatability and reproducibility analysis by panel member | Panel Member | % Positive Cells Counted Manually | Within-day/Within-System | | | Between-Day | | | Between-System | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | Mean % Positive Cells | SD | % CV | Mean % Positive Cells | SD | % CV | Mean % Positive Cells | SD | % CV | | 1 | 61 | 56.9 | 4.6 | 8.0 | 56.4 | 3.7 | 6.7 | 56.2 | 3.1 | 5.5 | | 2 | 52 | 46.9 | 5.9 | 12.6 | 47.5 | 4.3 | 9.1 | 46.1 | 4.4 | 9.5 | | 3 | 85 | 79.6 | 5.2 | 6.5 | 80.0 | 3.8 | 4.8 | 79.4 | 3.5 | 4.5 | | 4 | 0 | 0.9 | 1.0 | N/A | 1.2 | 0.8 | N/A | 1.1 | 0.7 | N/A | | 5 | 0 | 1.3 | 1.3 | N/A | 0.8 | 1.1 | N/A | 1.1 | 1.1 | N/A | | 6 | 0 | 0.6 | 0.7 | N/A | 0.5 | 0.5 | N/A | 0.7 | 0.7 | N/A | | 7 | 0 | 0.6 | 1.0 | N/A | 0.9 | 0.8 | N/A | 0.8 | 0.8 | N/A | | 8 | 18 | 22.2 | 2.9 | 13.2 | 25.2 | 4.8 | 19.1 | 24.4 | 5.0 | 20.5 | | 9 | 27 | 26.7 | 4.2 | 15.9 | 27.8 | 3.8 | 13.6 | 28.3 | 4.1 | 14.4 | | 10 | 31 | 29.6 | 5.7 | 19.2 | 32.6 | 6.4 | 19.6 | 32.2 | 5.9 | 18.2 | An additional panel of 5 equivocal specimens around the cutoff (10-25%) were tested for repeatability within-day/within-system. Results are presented in Table 3 below: Table 3: Within-day/Within Repeatability for specimens around the cutoff | Panel Member | % Positive Cells Counted Manually | Mean% Positive Cells | SD | %CV | | --- | --- | --- | --- | --- | | 1 | 12 | 11.6 | 1.62 | 13.9 | | 2 | 19 | 18.6 | 1.13 | 6.0 | | 3 | 22 | 19.7 | 0.6 | 3.1 | | 4 | 18 | 17.6 | 0.98 | 5.6 | | 5 | 19 | 19.6 | 1.32 | 6.7 | c. Linearity: Not applicable. d. Carryover: Not applicable. {7} e. Interfering Substances: Not applicable. 2. Other Supportive Instrument Performance Data Not Covered Above: Not applicable. K. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. L. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. 8 {8} 9 --- **Source:** [https://fda.innolitics.com/submissions/PA/subpart-e%E2%80%94immunology-laboratory-equipment-and-reagents/NTH/K122554](https://fda.innolitics.com/submissions/PA/subpart-e%E2%80%94immunology-laboratory-equipment-and-reagents/NTH/K122554) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com